Relevant search


    Corporate Overview

    Hong Kong Winhealth Pharma Group is a China-based, global innovative biomedical company founded in 2006, providing novel breakthrough therapies to patients with rare diseases and other unmet medical needs. The Group's Asia Pacific headquarter is located in Hong Kong, with operating hubs in Hangzhou, Shanghai and Beijing. The company owns a rare disease managed access platform in Bo'ao, Hainan. The company also has representative offices in Japan, Singapore and Europe.

    The Group has built a unique and diversified portfolio covering numerous innovative rare disease and specialty products at commercial and late clinical stages. It also makes constant efforts in introducing more innovative therapies from around the world.

    Winhealth also has a strategic stake in the Cumberland Emerging Technologies (CET) program in the United States and has established an incubator in cooperation with the University of Tokyo Hospital in Japan, adopt global cutting-edge innovative technologies and products in the medical field, as well as enhance the communication and collaboration with relevant medical schools and research institutes all around the world. Winhealth always adheres to the patient-centered philosophy to contribute to the progress of global health cause and improvement of the quality of human life.

    Vision, Mission & Values
    We Leave No One Behind.
    To build a leading rare disease ecosystem in Asia Pacific.
    Providing novel breakthrough therapies for patients with rare diseases and other unmet medical needs.
    Winhealth adheres to the high standard of the following core values in our daily operations and management.

    Result-Driven: We are result-oriented with demonstrating the extreme execution.

    Audacious Innovation: We aim to work out practical solutions to challenge through continuous innovation, creative thinking cultivation and wise risk management.

    Responsibility: We take utmost responsibility with the spirit of ownership for our stakeholders including patients, physicians, partners , employees and shareholders.

    Entrepreneurship: We constantly make breakthroughs with pioneering ideas and actions by taking initiatives to challenge the status quo, bring forth the new from the old and embrace the unknown and challenges.

    Major Investors
    • LYFE Capital
      Founded in 2015, LYFE Capital is a dedicated healthcare fund with $1.1 billion in assets under management. LYFE Capital is actively seeking healthcare companies with exceptional management teams and expansive vision geared towards global markets. LYFE Capital's investments focus spans biopharmaceuticals, medical devices, and diagnostics.
      KAITAI CAPITAL, founded in 2009, is a professional investment management organization that mainly engaged in venture capital, private equity, and wealth management business. Fields of investment include medicine and biotechnology, digital healthcare, artificial intelligence and digital industry, community innovation and consumption upgrading. Currently, the asset under management of KAITAI CAPITAL has reached CNY50 billion (USD$7.2B).
    Selected Partners

    This website uses cookies to improve website functionality. You may delete or block cookies by accessing your preferences. For more information please read here.